ORIC net incomeQ2 2026-$41.49M
ORIC net income was -$41.49M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$36.35M a year earlier. For the full fiscal 2025 it was -$129.47M, compared with -$127.85M in fiscal 2024.
Oric Pharmaceuticals Inc. (ORIC) financials
For the twelve months ended Jun 30, 2026, Oric Pharmaceuticals Inc. reported -$140.35M of net income.
- Net income, TTM
- -$140.35M
- Free cash flow, TTM
- -$112.26M
- Cash
- $37.48M
- Market cap
- $914.2M
FY2018FY2025
FY2018FY2025
ORIC revenue and earnings growth
ORIC EPSQ2 2026-$0.38
ORIC diluted EPS was -$0.38 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.47 a year earlier. For the full fiscal 2025 it was -$1.47, compared with -$1.83 in fiscal 2024.
ORIC free cash flowQ2 2026-$31.96M
ORIC free cash flow was -$31.96M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$30.91M a year earlier. For the full fiscal 2025 it was -$111.68M, compared with -$113.85M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $109.82M | $114.07M | $85.17M | $61.68M | $56.86M | $35.92M | $22.84M | $19.03M |
| Selling, general and admin | $33.19M | $28.82M | $25.61M | $25.09M | $22.01M | $13.42M | $5.72M | $3.35M |
| Operating income | -$143.00M | -$142.90M | -$110.78M | -$91.77M | -$78.87M | -$74.19M | -$28.57M | -$22.37M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$129.47M | -$127.85M | -$100.70M | -$89.12M | -$78.72M | -$73.70M | -$26.88M | -$21.36M |
| EPS, basic | -$1.47 | -$1.83 | -$1.96 | -$2.25 | -$2.07 | -$3.36 | -$14.15 | -$12.32 |
| EPS, diluted | -$1.47 | -$1.83 | -$1.96 | -$2.25 | -$2.07 | -$3.36 | -$14.15 | -$12.32 |
| Diluted shares | 87.8M | 69.7M | 51.5M | 39.7M | 38.0M | 21.9M | 1.9M | 1.7M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.67M | $59.90M | $23.88M | $67.31M | $226.47M | $78.45M | $89.16M | $42.64M |
| Short-term investments | - | - | - | - | - | $215.15M | - | - |
| Current assets | $288.47M | $262.25M | $212.60M | $210.46M | $240.52M | $296.70M | $90.00M | - |
| Total assets | $408.89M | $274.14M | $252.01M | $247.18M | $298.64M | $299.00M | $94.09M | - |
| Current liabilities | $20.42M | $24.85M | $20.46M | $15.39M | $15.15M | $9.00M | $5.35M | - |
| Total debt | - | - | - | - | $10.50M | $600.0K | - | - |
| Total liabilities | $24.53M | $31.02M | $27.92M | $24.83M | $25.67M | $9.22M | $6.12M | - |
| Shareholders' equity | $384.36M | $243.12M | $224.09M | $222.35M | $272.98M | $289.78M | -$90.08M | -$64.43M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$110.97M | -$112.66M | -$85.69M | -$75.14M | -$59.54M | -$45.27M | -$23.53M | -$20.68M |
| Capital expenditures | $712.0K | $1.19M | $849.0K | $2.08M | $939.0K | $667.0K | $768.0K | $525.0K |
| Free cash flow | -$111.68M | -$113.85M | -$86.54M | -$77.22M | -$60.48M | -$45.94M | -$24.30M | -$21.21M |
| Investing cash flow | -$148.03M | $22.14M | -$43.40M | -$109.25M | $158.44M | -$215.96M | -$768.0K | -$508.0K |
| Financing cash flow | $245.26M | $126.55M | $85.66M | $25.23M | $49.13M | $250.51M | $70.82M | $38.01M |
| Stock-based compensation | $25.04M | $20.21M | $15.23M | $14.46M | $12.85M | $5.28M | $1.09M | $469.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Return on equity | -33.7% | -52.6% | -44.9% | -40.1% | -28.8% | -25.4% | - | - |
| Return on assets | -31.7% | -46.6% | -40.0% | -36.1% | -26.4% | -24.7% | -28.6% | - |
| Current ratio | 14.13 | 10.56 | 10.39 | 13.68 | 15.87 | 32.96 | 16.81 | - |
| Debt to equity | - | - | - | - | 0.04 | 0.00 | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $36.30M | $31.44M | $25.86M | $28.77M | $30.55M | $24.64M | $31.97M | $31.20M | $28.94M | $21.96M | $24.48M | $22.39M |
| Selling, general and admin | $9.00M | $8.18M | $8.70M | $7.90M | $8.52M | $8.08M | $7.60M | $7.12M | $7.08M | $7.03M | $6.95M | $6.29M |
| Operating income | -$45.30M | -$39.62M | -$34.55M | -$36.67M | -$39.06M | -$32.72M | -$39.57M | -$38.32M | -$36.02M | -$28.99M | -$31.43M | -$28.68M |
| Net income | -$41.49M | -$35.77M | -$30.50M | -$32.59M | -$36.35M | -$30.02M | -$36.31M | -$34.57M | -$31.96M | -$25.01M | -$28.33M | -$25.48M |
| EPS, basic | -$0.38 | -$0.34 | - | -$0.33 | -$0.47 | -$0.42 | -$0.52 | -$0.49 | -$0.45 | -$0.37 | -$0.49 | -$0.44 |
| EPS, diluted | -$0.38 | -$0.34 | - | -$0.33 | -$0.47 | -$0.42 | -$0.52 | -$0.49 | -$0.45 | -$0.37 | -$0.49 | -$0.44 |
| Diluted shares | 108.0M | 105.5M | - | 99.0M | 78.1M | 71.0M | - | 70.5M | 70.3M | 67.3M | - | 57.4M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $37.48M | $56.40M | $45.67M | $49.67M | $75.86M | $49.33M | $59.90M | $44.23M | $49.83M | $56.36M | $23.88M | $26.24M |
| Current assets | $273.69M | $290.23M | $288.47M | $295.59M | $291.12M | $211.43M | $262.25M | $279.43M | $294.60M | $324.08M | $212.60M | $232.24M |
| Total assets | $404.69M | $436.76M | $408.89M | $431.19M | $346.86M | $242.86M | $274.14M | $302.07M | $328.91M | $350.79M | $252.01M | $274.33M |
| Current liabilities | $20.76M | $17.77M | $20.42M | $20.18M | $18.05M | $17.62M | $24.85M | $21.25M | $19.54M | $15.21M | $20.46M | $18.94M |
| Total liabilities | $23.43M | $21.20M | $24.53M | $24.27M | $22.86M | $23.12M | $31.02M | $28.08M | $26.51M | $22.14M | $27.92M | $26.92M |
| Shareholders' equity | $381.26M | $415.56M | $384.36M | $406.92M | $324.00M | $219.74M | $243.12M | $273.99M | $302.40M | $328.64M | $224.09M | $247.41M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.61M | -$32.44M | -$22.48M | -$25.11M | -$30.84M | -$32.53M | -$28.05M | -$28.80M | -$25.63M | -$30.19M | -$24.27M | -$19.64M |
| Capital expenditures | $356.0K | $2.0K | $227.0K | $35.0K | $63.0K | $387.0K | $219.0K | $418.0K | $333.0K | $218.0K | $57.0K | $77.0K |
| Free cash flow | -$31.96M | -$32.44M | -$22.71M | -$25.15M | -$30.91M | -$32.92M | -$28.27M | -$29.21M | -$25.96M | -$30.40M | -$24.33M | -$19.72M |
| Investing cash flow | $11.86M | -$17.98M | $16.98M | -$110.53M | -$76.93M | $22.45M | $42.66M | $23.07M | $18.28M | -$61.87M | $20.96M | -$57.83M |
| Financing cash flow | $828.0K | $61.14M | $1.50M | $109.45M | $134.30M | $11.0K | $575.0K | $126.0K | $816.0K | $125.03M | $453.0K | $31.0K |
| Stock-based compensation | $7.09M | $6.90M | $6.28M | $5.63M | $6.57M | $6.55M | $5.20M | $5.06M | $5.00M | $4.96M | $3.92M | $3.86M |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 13.19 | 16.33 | 14.13 | 14.65 | 16.13 | 12.00 | 10.56 | 13.15 | 15.08 | 21.31 | 10.39 | 12.26 |
Source: XBRL data Oric Pharmaceuticals Inc. files with the SEC, latest filing dated Aug 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ORIC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ORIC | - | - | -$140.35M | - | $914.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
ORIC FAQ
5 questionsIs ORIC profitable?
No. Oric Pharmaceuticals Inc. reported a net loss of $140.35M for the twelve months ended Jun 30, 2026.How much cash and debt does ORIC have?
Oric Pharmaceuticals Inc. reported $37.48M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ORIC free cash flow?
Oric Pharmaceuticals Inc. generated -$112.26M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$111.64M less capital expenditures.When did ORIC last report financial results?
The latest statements here come from Oric Pharmaceuticals Inc.'s 10-Q filed on Aug 3, 2026, covering the period ended Jun 30, 2026.Where does this ORIC financial data come from?
Quantisnow builds these statements from the structured XBRL data Oric Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.